Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

B WILMINGTON, Del., April 2, 2026 /PRNewswire/ — Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in…
posteditor
posteditor
Articles: 16137

Other News